https://kfor.com/business/press-releases/globenewswire/9144249/hibercell-announces-first-patient-dosed-in-phase-1b-clinical-trial-evaluating-hc-7366-in-combination-with-venetoclax-and-azacitidine-for-the-treatment-of-acute-myeloid-leukemia-aml/
Our lead investigator kicking off another combination trial with Venetoclax and Azacitidine .
Merck started a collaboration with Hibercell mid-way through last year for HC-7366 in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC)
Merck on the hunt with Keytruda patents coming up for expiry in the next couple of years.
https://hibercell.com/news/hibercell-inc-announces-clinical-collaboration-with-merck-to-evaluate-hc-7366-an-activator-of-isr-kinase-gcn2-in-combination-with-welireg-belzutifan-in-a-phase-1b-study-of-patients-with-cl/
I won't be surprised if we see a collaboration for our ADVENT-AML in the very near term.
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-45
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $7.017K | 1.754M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 2882363 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13492653 | 21 |
View Market Depth
| Last trade - 09.59am 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |